Optimal response to thalidomide in a patient with thalassaemia major resistant to conventional therapy.
作者信息
Masera Nicoletta, Tavecchia Luisa, Capra Marietta, Cazzaniga Giovanni, Vimercati Chiara, Pozzi Lorena, Biondi Andrea, Masera Giuseppe
机构信息
Clinica Pediatrica, Università di Milano-Bicocca, Ospedale San Gerardo, Monza, Italy.
出版信息
Blood Transfus. 2010 Jan;8(1):63-5. doi: 10.2450/2009.0102-09.
Abstract
摘要
相似文献
1
Optimal response to thalidomide in a patient with thalassaemia major resistant to conventional therapy.一名对传统疗法耐药的重型地中海贫血患者对沙利度胺的最佳反应。
Blood Transfus. 2010 Jan;8(1):63-5. doi: 10.2450/2009.0102-09.
2
Thalidomide therapy in a patient with thalassemia major.一名重型地中海贫血患者的沙利度胺治疗。
Blood Cells Mol Dis. 2008 Jul-Aug;41(1):136-7. doi: 10.1016/j.bcmd.2008.03.001. Epub 2008 Apr 24.
3
Safety and effectiveness of thalidomide and hydroxyurea combination in β-thalassaemia intermedia and major: a retrospective pilot study.沙利度胺与羟基脲联合治疗中间型和重型β地中海贫血的安全性和有效性：一项回顾性试点研究。
Br J Haematol. 2020 Feb;188(3):e18-e21. doi: 10.1111/bjh.16272. Epub 2019 Nov 11.
4
Foetal haemoglobin inducers and thalassaemia: novel achievements.胎儿血红蛋白诱导剂与地中海贫血：新进展
Blood Transfus. 2010 Jan;8(1):5-7. doi: 10.2450/2009.0137-09.
5
Thalidomide induces haematologic responses in patients with β-thalassaemia.沙利度胺可诱导β-地中海贫血患者血液学反应。
Eur J Haematol. 2017 Nov;99(5):437-441. doi: 10.1111/ejh.12955. Epub 2017 Sep 27.
6
Experience with combination of hydroxyurea and low-dose thalidomide in transfusion-dependent beta thalassemia patients.羟脲联合小剂量沙利度胺治疗输血依赖型β地中海贫血患者的经验。
Ann Hematol. 2021 Jun;100(6):1417-1427. doi: 10.1007/s00277-021-04501-3. Epub 2021 Apr 3.
7
Comparison of efficacy and safety of thalidomide vs hydroxyurea in patients with Hb E-β thalassemia - a pilot study from a tertiary care Centre of India.沙利度胺与羟基脲治疗 HbE-β 地中海贫血患者的疗效和安全性比较-来自印度一家三级医疗中心的初步研究。
Blood Cells Mol Dis. 2021 May;88:102544. doi: 10.1016/j.bcmd.2021.102544. Epub 2021 Feb 3.
8
Thalidomide has a significant effect in patients with thalassemia intermedia.沙利度胺对中间型地中海贫血患者有显著疗效。
Hematology. 2018 Jan;23(1):50-54. doi: 10.1080/10245332.2017.1354427. Epub 2017 Jul 18.
9
A phase 2 study of HQK-1001, an oral fetal haemoglobin inducer, in β-thalassaemia intermedia.一项关于口服胎儿血红蛋白诱导剂HQK-1001治疗中间型β地中海贫血的2期研究。
Br J Haematol. 2014 Feb;164(3):456-8. doi: 10.1111/bjh.12635. Epub 2013 Nov 13.
10
Thalidomide-induced Stroke in a Child With Thalassemia Major.沙利度胺诱发的重型地中海贫血患儿卒中
J Pediatr Hematol Oncol. 2017 Nov;39(8):e519-e520. doi: 10.1097/MPH.0000000000000860.
引用本文的文献
1
Cephalometric analysis of patients with beta thalassemia receiving fetal hemoglobin induction therapy.接受胎儿血红蛋白诱导治疗的β地中海贫血患者的头影测量分析
J Taibah Univ Med Sci. 2024 Feb 1;19(2):351-358. doi: 10.1016/j.jtumed.2024.01.003. eCollection 2024 Apr.
2
Pharmacological Induction of Fetal Hemoglobin in β-Thalassemia and Sickle Cell Disease: An Updated Perspective.β地中海贫血和镰状细胞病中胎儿血红蛋白的药理学诱导：最新观点
Pharmaceuticals (Basel). 2022 Jun 16;15(6):753. doi: 10.3390/ph15060753.
3
Evaluation of the combination therapy of hydroxyurea and thalidomide in β-thalassemia.羟基脲联合沙利度胺治疗β-地中海贫血的疗效评价。
Blood Adv. 2022 Dec 27;6(24):6162-6168. doi: 10.1182/bloodadvances.2022007031.
4
Safety and efficacy of thalidomide in patients with transfusion-dependent β-thalassemia: a randomized clinical trial.沙利度胺治疗输血依赖型β-地中海贫血患者的安全性和有效性：一项随机临床试验。
Signal Transduct Target Ther. 2021 Nov 18;6(1):405. doi: 10.1038/s41392-021-00811-0.
5
Efficacy of Thalidomide Treatment in Children With Transfusion Dependent β-Thalassemia: A Retrospective Clinical Study.沙利度胺治疗依赖输血的儿童β地中海贫血的疗效：一项回顾性临床研究
Front Pharmacol. 2021 Aug 12;12:722502. doi: 10.3389/fphar.2021.722502. eCollection 2021.
6
Ineffective Erythropoiesis in β-Thalassaemia: Key Steps and Therapeutic Options by Drugs.β-地中海贫血无效造血：药物作用的关键步骤和治疗选择。
Int J Mol Sci. 2021 Jul 5;22(13):7229. doi: 10.3390/ijms22137229.
7
Experience with combination of hydroxyurea and low-dose thalidomide in transfusion-dependent beta thalassemia patients.羟脲联合小剂量沙利度胺治疗输血依赖型β地中海贫血患者的经验。
Ann Hematol. 2021 Jun;100(6):1417-1427. doi: 10.1007/s00277-021-04501-3. Epub 2021 Apr 3.
8
Challenges in transfusion and the role of Thalidomide in E-β-Thalassemia-A case report.输血中的挑战以及沙利度胺在E-β地中海贫血中的作用——病例报告
Clin Case Rep. 2020 Jul 30;8(11):2208-2210. doi: 10.1002/ccr3.3141. eCollection 2020 Nov.
9
Thalidomide for the Treatment of Thrombocytopenia and Hypersplenism in Patients With Cirrhosis or Thalassemia.沙利度胺用于治疗肝硬化或地中海贫血患者的血小板减少症和脾功能亢进。
Front Pharmacol. 2020 Jul 24;11:1137. doi: 10.3389/fphar.2020.01137. eCollection 2020.
10
Promising Response to Thalidomide in Symptomatic β-Thalassemia.沙利度胺对有症状的β地中海贫血有显著疗效。
Indian J Hematol Blood Transfus. 2020 Apr;36(2):337-341. doi: 10.1007/s12288-019-01231-5. Epub 2019 Nov 18.
本文引用的文献
1
Haemoglobin F modulation in childhood sickle cell disease.儿童镰状细胞病中的胎儿血红蛋白调节
Br J Haematol. 2009 Feb;144(3):308-16. doi: 10.1111/j.1365-2141.2008.07482.x. Epub 2008 Nov 20.
2
Thalidomide therapy in a patient with thalassemia major.一名重型地中海贫血患者的沙利度胺治疗。
Blood Cells Mol Dis. 2008 Jul-Aug;41(1):136-7. doi: 10.1016/j.bcmd.2008.03.001. Epub 2008 Apr 24.
3
Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells.泊马度胺和来那度胺调节人CD34+细胞中的红细胞生成和胎儿血红蛋白生成。
J Clin Invest. 2008 Jan;118(1):248-58. doi: 10.1172/JCI32322.
4
Thalidomide induces gamma-globin gene expression through increased reactive oxygen species-mediated p38 MAPK signaling and histone H4 acetylation in adult erythropoiesis.沙利度胺通过增加活性氧介导的p38丝裂原活化蛋白激酶信号传导和组蛋白H4乙酰化，在成人红细胞生成中诱导γ-珠蛋白基因表达。
Blood. 2007 Oct 15;110(8):2864-71. doi: 10.1182/blood-2007-01-065201. Epub 2007 Jul 9.
5
Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia.地西他滨在镰状细胞贫血间歇给药治疗期间维持胎儿血红蛋白水平升高
Blood. 2002 Jun 1;99(11):3905-8. doi: 10.1182/blood.v99.11.3905.
6
7
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.羟基脲对镰状细胞贫血疼痛性危象发作频率的影响。镰状细胞贫血羟基脲多中心研究的研究者们。
N Engl J Med. 1995 May 18;332(20):1317-22. doi: 10.1056/NEJM199505183322001.
8
Pharmacologic treatment of thalassemia intermedia with hydroxyurea.用羟基脲对中间型地中海贫血进行药物治疗。
J Pediatr. 1994 Sep;125(3):490-2. doi: 10.1016/s0022-3476(05)83304-9.
9
Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia.羟基脲可提高镰状细胞贫血患者的胎儿血红蛋白生成水平。
J Clin Invest. 1984 Aug;74(2):652-6. doi: 10.1172/JCI111464.
10
5-azacytidine selectively increases gamma-globin synthesis in a patient with beta+ thalassemia.5-氮杂胞苷可选择性增加一名β+地中海贫血患者的γ珠蛋白合成。
N Engl J Med. 1982 Dec 9;307(24):1469-75. doi: 10.1056/NEJM198212093072401.
Zotero 插件